All Stories

  1. Intensive chemotherapy vs venetoclax/hypomethylating agents for patients aged 60 to 75 years with favorable, NPM1-mutated AML

    Article • Blood Neoplasia, November 2025, Elsevier

    William Dalton

  2. Serine auxotrophy is a targetable vulnerability driven by PSAT1 suppression in AML

    Article • May 2025, Cold Spring Harbor Laboratory Press

    William Dalton

  3. Tumor-derived CCL2 drives tumor growth and immunosuppression in IDH1-mutant cholangiocarcinoma

    Article • Hepatology, December 2024, Wolters Kluwer Health

    William Dalton

  4. The E592K variant of SF3B1 creates unique RNA missplicing and associates with high-risk MDS without ring sideroblasts

    Article • Blood Advances, July 2024, American Society of Hematology

    William Dalton

  5. Outcome heterogeneity of <i>TP53</i>-mutated myeloid neoplasms and the role of allogeneic hematopoietic cell transplantation

    Article • Haematologica, September 2023, Ferrata Storti Foundation (Haematologica)

    William Dalton

  6. Co-occurring mutations in ASXL1, SRSF2, and SETBP1 define a subset of myelodysplastic/ myeloproliferative neoplasm with neutrophilia

    Article • Leukemia Research, August 2023, Elsevier

    William Dalton

  7. An accessible patient-derived xenograft model of low-risk myelodysplastic syndromes

    Article • Haematologica, July 2023, Ferrata Storti Foundation (Haematologica)

    William Dalton

  8. The E592K variant of SF3B1 creates unique RNA missplicing and associates with high-risk MDS without ring sideroblasts

    Article • April 2023, Springer Science + Business Media

    William Dalton

  9. Allogeneic Blood or Marrow Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Acute Lymphoblastic Leukemia in Patients Age ≥55 Years

    Article • Transplantation and Cellular Therapy, March 2023, Elsevier

    William Dalton

  10. Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease

    Article • Leukemia & Lymphoma, February 2023, Taylor & Francis

    Matthew J Newman, William Dalton

  11. CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidine

    Article • Haematologica, December 2022, Ferrata Storti Foundation (Haematologica)

    William Dalton

  12. Cell-specific regulation of gene expression using splicing-dependent frameshifting

    Article • Nature Communications, October 2022, Springer Science + Business Media

    William Dalton

  13. Post-Transplantation Cyclophosphamide-Based Graft- versus-Host Disease Prophylaxis with Nonmyeloablative Conditioning for Blood or Marrow Transplantation for Myelofibrosis

    Article • Transplantation and Cellular Therapy, May 2022, Elsevier

    William Dalton

  14. Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy

    Article • Leukemia & Lymphoma, April 2022, Taylor & Francis

    William Dalton

  15. Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center Experience

    Article • Clinical Lymphoma Myeloma & Leukemia, April 2022, Elsevier

    William Dalton

  16. Cell-specific regulation of gene expression using splicing-dependent frameshifting.

    Article • March 2022, Springer Science + Business Media

    William Dalton

  17. Cell-specific regulation of gene expression using splicing-dependent frameshifting

    Article • March 2022, Cold Spring Harbor Laboratory Press

    William Dalton

  18. Taking the STING out of acute myeloid leukemia through macrophage-mediated phagocytosis

    Article • Journal of Clinical Investigation, March 2022, American Society for Clinical Investigation

    William Dalton

  19. The role of the atypical chemokine receptor CCRL2 in myelodysplastic syndrome and secondary acute myeloid leukemia

    Article • Science Advances, February 2022, American Association for the Advancement of Science

    William Dalton

  20. NOTCH1 PEST domain variants are responsive to standard of care treatments despite distinct transformative properties in a breast cancer model

    Article • Oncotarget, February 2022, Impact Journals, LLC

    William Dalton

  21. How low risk are low risk myelodysplastic syndromes?

    Article • Expert Review of Hematology, January 2022, Taylor & Francis

    William Dalton

  22. The role of the atypical chemokine receptor CCRL2 in myelodysplastic syndrome and secondary acute myeloid leukemia

    Article • July 2021, Cold Spring Harbor Laboratory Press

    William Dalton

  23. G-protein coupled receptor 35 (GPR35) regulates the colonic epithelial cell response to enterotoxigenic Bacteroides fragilis

    Article • Communications Biology, May 2021, Springer Science + Business Media

    William Dalton

  24. Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamide

    Article • Blood Advances, October 2020, American Society of Hematology

    William Dalton

  25. Parkin on serine: a Parkinson disease gene suppresses serine synthesis in cancer

    Article • Journal of Clinical Investigation, May 2020, American Society for Clinical Investigation

    William Dalton

  26. The K666N mutation in SF3B1 is associated with increased progression of MDS and distinct RNA splicing

    Article • Blood Advances, March 2020, American Society of Hematology

    William Dalton

  27. The metabolic reprogramming and vulnerability of SF3B1 mutations

    Article • Molecular & Cellular Oncology, February 2020, Taylor & Francis

    William Dalton

  28. Hotspot SF3B1 mutations induce metabolic reprogramming and vulnerability to serine deprivation

    Article • Journal of Clinical Investigation, August 2019, American Society for Clinical Investigation

    William Dalton

  29. Fibrinogen consumption and use of heparin are risk factors for delayed bleeding during acute promyelocytic leukemia induction

    Article • Leukemia Research, August 2019, Elsevier

    William Dalton

  30. The estrogen receptor-alpha S118P variant does not affect breast cancer incidence or response to endocrine therapies

    Article • Breast Cancer Research and Treatment, December 2018, Springer Science + Business Media

    William Dalton

  31. Personalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor Board

    Article • JCO Precision Oncology, July 2017, American Society of Clinical Oncology (ASCO)

    William Dalton

  32. Single-Nucleotide Polymorphism Leading to False Allelic Fraction by Droplet Digital PCR

    Article • Clinical Chemistry, June 2017, AACC

    William Dalton

  33. PIK3CA mutations and TP53 alterations cooperate to increase cancerous phenotypes and tumor heterogeneity

    Article • Breast Cancer Research and Treatment, February 2017, Springer Science + Business Media

    William Dalton

  34. A Polycythemia VeraJAK2Mutation Masquerading as a Duodenal Cancer Mutation

    Article • Journal of the National Comprehensive Cancer Network, December 2016, Harborside Press, LLC

    William Dalton

  35. ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients

    Article • Clinical Cancer Research, February 2016, American Association for Cancer Research (AACR)

    William Dalton

  36. HER2 missense mutations have distinct effects on oncogenic signaling and migration

    Article • Proceedings of the National Academy of Sciences, October 2015, Proceedings of the National Academy of Sciences

    William Dalton

  37. NDRG1 links p53 with proliferation-mediated centrosome homeostasis and genome stability

    Article • Proceedings of the National Academy of Sciences, August 2015, Proceedings of the National Academy of Sciences

    William Dalton

  38. CDK1 Regulates Mediator of DNA Damage Checkpoint 1 during Mitotic DNA Damage

    Article • Cancer Research, October 2012, American Association for Cancer Research (AACR)

    William Dalton

  39. A novel microtubule-modulating noscapinoid triggers apoptosis by inducing spindle multipolarity via centrosome amplification and declustering

    Article • Cell Death and Differentiation, November 2010, Springer Science + Business Media

    William Dalton

  40. p53 suppresses structural chromosome instability after mitotic arrest in human cells

    Article • Oncogene, January 2010, Springer Science + Business Media

    William Dalton

  41. Role of Prolonged Mitotic Checkpoint Activation in the Formation and Treatment of Cancer

    Article • Future Oncology, November 2009, Taylor & Francis

    William Dalton

  42. Mouse embryonic fibroblasts null for the Krüppel-like factor 4 gene are genetically unstable

    Article • Oncogene, January 2009, Springer Science + Business Media

    William Dalton

  43. Human Cancer Cells Commonly Acquire DNA Damage during Mitotic Arrest

    Article • Cancer Research, December 2007, American Association for Cancer Research (AACR)

    William Dalton

  44. Mitotic origins of chromosomal instability in colorectal cancer

    Article • Current Colorectal Cancer Reports, May 2007, Springer Science + Business Media

    William Dalton

  45. Sex-Determining Region Y Box 4 Is a Transforming Oncogene in Human Prostate Cancer Cells

    Article • Cancer Research, April 2006, American Association for Cancer Research (AACR)

    William Dalton

  46. Krüppel‐like factor 5 promotes mitosis by activating the cyclin B1/Cdc2 complex during oncogenic Ras‐mediated transformation

    Article • FEBS Letters, August 2005, Wiley

    William Dalton

  47. Krüppel-like factor 4 prevents centrosome amplification following γ-irradiation-induced DNA damage

    Article • Oncogene, April 2005, Springer Science + Business Media

    William Dalton

  48. Krüppel-like factors 4 and 5: the yin and yang regulators of cellular proliferation

    Article • BDJ, February 2005, Springer Science + Business Media

    William Dalton

  49. Quetiapine as treatment for dopaminergic‐induced dyskinesias in Parkinson's disease

    Article • Movement Disorders, October 2003, Wiley

    William Dalton